Kesonotide

Kesonotide is a novel concept in cancer treatment. A first-in-class dual anti inflammatory/chemotherapy drug for the treatment of solid cancers.

We imagined a single drug that could be:

• An anti-inflammatory drug blocking the activity of the tumour microenvironment
• An anti-inflammatory drug providing relief from pain and swelling
• A chemotherapy drug delivering direct killing of cancer cells.

Kesonotide has undergone a first-in-human study in 12 men with advanced prostate cancer, confirming oral bioavailability, safety and tolerance.

The ADVICE Phase Ib/IIa study is scheduled to start in the first half of 2025, involving up to 80 patients with advanced solid cancers progressing on standard-of-care treatment to receive kesonotide monotherapy.

ADVICE will be a world-first trial in cancer patients of a drug designed to offer dual comprehensive inhibition of the tumour microenvironment and killing of cancer cells.